Direct-acting antiviral treatment for hepatitis C did not correlate with an increased risk for hepatocellular carcinoma in a large cohort study of both treated and untreated patients with or without cirrhosis. Those with incident HCC after DAA treatment had higher risk factors at baseline. “There was no increased risk for HCC as a result of having received DAA therapy whatsoever,” Raymond T. Chung, PhD, director of Hepatology and Liver Center at Massachus
The median overall survival was 15.0 and 15.6 months in the two sorafenib-experienced groups. In comparison, people who switched from sorafenib to a recently approved similar drug, regorafenib (Stivarga), had a median survival of about 11 months. The median survival for the sorafenib-naive group could not be determined because a majority of patients were still alive, but this was projected to be 28.6 months. Nivolumab (Opdivo), a PD-1 checkpoint inhibitor
SINGAPORE, Nov. 9, 2017 /PRNewswire/ -- Singapore biomedical firm Restalyst has developed a new algorithm to detect liver cancer more accurately, improving the sensitivity to 90%. The new methodology looks at three factors: membrane bound protein ERBB3, AFP (alpha fetoprotein) and age of patient. It will detect and identify liver cancer more effectively, and better distinguish liver cancer from chronic hepatitis condition. An AFP test is commonly used
Friday, October 13, 2017 News Recap: Research & Discoveries After an intense hunt, researchers at the Norwegian University of Science and Technology (NTNU) can now describe an important part of the disease's guerrilla tactics: how hepatitis C converts innocent cells into outright virus factories. How hepatitis C hides in the body. Apparently, liver cancer can be caught at an early stage through a newly developed blood test, improving the odd...
Hepatocellular carcinoma (HCC) is the third cause of cancer-related death and accounts for more than 90% of primary liver cancers. It is most frequently diagnosed at an advanced stage in patients with chronic liver injury and cirrhosis. Despite dedicated research in the last few decades, significant advancements in the treatment of HCC have not been achieved, and HCC still belongs to the category of cancers with a very low 5-year survival rate of less t